 |
| CEO : Kazuhiko Sakata, Ph. D. |
| Educational and Research Career | |
| March 1984 | Graduated from Faculty of Pharmaceutical Science, Toyama Medical and Pharamaceutical University (now Toyama University). |
| March 1989 | Graduated from Graduate School of Pharmacy and awarded Ph. D., (Toyama Medical and Pharmaceu University). |
| April 1989 | Joined Mitsui Pharmaceutical Industries, Ltd. Assined to Institute of Bioligical Science. Awarded twice with in-house excellence research on "The mechanism of action for acute-phase cerebral infaction disease drug". |
| April 1994～ March 1996 |
Dispatched to the Brain Research Center of Lund University (Sweden). Engaged in research to elucidate the pathogenesis of ischemic encephalopathy. |
| October 1997 | Chief Investigator of Clinical Development Department (Mitsui Pharmacertical Co., Ltd.) and engaged Late-PhaseⅡ study of MS-153. |
| July 1998 | Retired Mitsui Pharmaceutical Co.,Ltd. |
| April 1999 | Guest Researcher of Tokyo Metropolitan Institute of Clinical Research (now Tokyo Metropolitan Institute of Medical Science). Participated the project of (～2004) ： Elucidation of mechanism and therapecutic new drug development "Hypoxic sensor-medidated ischemic and degenerative neurological diseases" (Japan Health Science Foundation). |
| August 2002 | Founded CareTIS, Co., Ltd. and inaugurated CEO. |
| To the present | |
| Academic presentation |
| I have presented at the Japan Pharmaceutical Association, the International Association of Brain Circulation and Metabolism etc. |
|
【Major Books】 K.Sakata et al., Intracellular signal transduction in the postischemic brain. Implications for neurotransmisson and neuronal survival.,Eric K.fernstrom Symposium,1994. |
| Current research and development intersets |
|
1. Providing products and services on technologies, seeds, and information that are widely and generally used in research fields. 2. Trial of inspection ・ technological development and drug discovery at quantum level. 3. Introduction of IT and AI technology to support research and development. |
| July 9, 2019 |
